Global opportunities
Cardiometabolic diseases are among the most serious public health issues confronting the globe today. However, lack of innovation and high R&D costs have resulted in few biopharmaceutical companies focusing on this disease area.
Unmet need in cardiometabolic
Cardiometabolic disease describes a spectrum of conditions beginning with insulin resistance, progressing to the metabolic syndrome, pre-diabetes, and finally to more severe conditions including cardiovascular disease (CVD) and type 2 diabetes (T2DM). These conditions are grouped under the umbrella term “cardiometabolic disease” as they are related or shared risk factors, such as overweight and obesity, dyslipidemia, and high blood pressure.
Alarmingly, 30% (2.1 billion) of the global population are either overweight or obese and CVD is the leading cause of death worldwide. In 2013, 382 million people had diabetes, with this number expected to rise to 592 million by 2035. Further, the estimated annual global health expenditure attributable to diabetes averages $855 billion (USD) rising to $1044 billion (USD) by 2030. Thus, it is a public health imperative to reduce cardiometabolic risk and cardiometabolic disease development.
Reference:
Improving Cardiometabolic Health with Diet, Physical Activity, and Breaking Up Sitting: What about Sleep? Grace E. Vincent,1,* Sarah M. Jay,1 Charli Sargent,1 Corneel Vandelanotte,1 Nicola D. Ridgers,2 and Sally A. Ferguson1 Front Physiol. 2017; 8: 865. Published online 2017 Nov 8. doi: 10.3389/fphys.2017.00865
CVD
Cancer
